An important concept in tumour immunology is that tumours grow only if they can avoid host immune responses. An extension of this concept is that immune responses are selective forces during tumour progression. Numerous mechanisms have been envisaged and investigated by which tumours could escape immune defences. Early research revolved around lack of immunogenicity of tumours, shedding and modulation of cell surface antigens and blocking of tumour reactive lymphocytes by antigen-antibody complexes (Hellstrom & Hellstrom, 1969) . More recent studies take into account our knowledge that the immune system is composed of complex interacting and self-regulating networks of cells and soluble factors and have focused on whether antigens on progressor tumours have properties that allow them to avoid protective immunity, for example by preferentially stimulating suppressor cell circuits (Moser et al., 1983; Greene, 1980; Fujimoto et al., 1976; Reinisch et al., 1977; Frost et al., 1982; Kolsch et al., 1973; Mengersen et al., 1975; North, 1984; Haubeck & Kolsch, 1982) .
The ability of many tumours to stimulate Ts has been established although the conditions under which they are generated and the extent to which they facilitate growth of primary tumours still requires clarification. In our previous studies with a transplantable murine fibrosarcoma (FSA) we found both tumour-specific Ts and non-tumourspecific non-T suppressor cells in the spleens of tumour-bearing mice in the later stages of tumour growth (Howie & McBride, 1982; McBride & Howie, 1984) . The tumour grew initially in the face of developing systemic responses that were demonstrably protective. Concomitant immunity (Milas et al., 1982) and tumour-specific responses could be demonstrated by both in vitro (Howie & McBride, 1982; McBride & Howie, 1984) and in vivo (Peters et al., 1978; McBride et al., 1980) (North, 1984) . These studies, however, shed little light upon mechanisms operating during the initial stages of primary tumour growth which is presumably the most important period in terms of tumour escape.
In previous experiments we assessed only the response to FSA tumours growing from moderatesize inocula (4 x 105 cells). We subsequently varied the initial tumour load so as to build up a more complete picture of the host-tumour relationship. In this paper we show that both small (101-103 cells) and large (107 cells) size tumour inocula induce Ts cells and tolerance and only moderate size inocula induce immunity. This is therefore analogous to the classic two-zone tolerance phenomenon seen with certain soluble antigens (Mitchison, 1964) .
Induction of low zone tolerance by methylcholanthrene-induced cells confirms and extends the findings of Kolsch and coworkers (Kolsch et al., 1973; Mengersen et al., 1975; Haubeck & Kolsch, 1982) in other tumour systems. 
Tumour
The methylcholanthrene-induced syngeneic fibrosarcoma (FSA) used in these experiments has been described in detail previously (Howie & McBride, 1982; McBride & Howie, 1984; Milas et al., 1982; Peters et al., 1978; McBride et al., 1980) . It had been transplanted 7-9 times when used. Tumour cell suspensions were made as described (Howie & McBride, 1982; McBride & Howie, 1984) .
Experimental design
The aim of these experiments was to examine the effect of varying doses of FSA upon the immune response. Preliminary experiments established that 4 x 105 cells s.c. gave a strong response which peaked 7 days after challenge (Howie & McBride, 1982) . Less than 104 cells gave no response while greater than 106 cells were also less effective. Varying doses of FSA were injected s.c. into the right flank followed 10 days later by 4 x 101 cells into the left flank. Spleens were removed one week later and their anti-tumour activity assayed.
Winn assay T cells were enriched from spleen suspensions by passage over nylon wool columns (Howie & McBride, 1982 (Peters et al., 1978; McBride, et al., 1980 Specificity or non-specificity of suppression was assayed by examining the ability of the putative suppressors to inhibit responses of T cells taken from TNP-CRBC primed mice with TNP-CRBC as antigen (Howie & McBride, 1982; McBride & Howie, 1984) .
The anti-Thy 1.2 used was monoclonal 30: H: 12 which was a kind gift of Dr Micklem, Department of Zoology, Edinburgh University.
Results
We used two assays to measure tumour-specific responses. The first was a Winn assay in which nylon wool, non-adherent spleen cells from mice were mixed with viable tumour cells and injected s.c. into normal recipients (Peters et al., 1978; McBride et al., 1980) . Immunity is dependent upon primed Lyl+2-cells and is immunologically specific (McBridge & Howie, unpublished) . The development of immunity in mice receiving standard inocula of tumour cells was prevented by prior inoculation of either low (101-103) or high (greater than 106) doses of the same tumour (Figure 1 ).
Because the Winn assay is not very well-suited to subpopulation analysis we turned to a sensitive in vitro assay for tumour specific TH cell activity (Howie & McBride, 1982; McBride & Howie, 1984) to analyze this phenomenon further. The kinetics of (Table I) . This is a similar result to that already found in mice bearing large tumour burdens (Howie & McBride, 1982; McBride & Howie, 1984) . cells stimulate powerful responses. Larger cell doses induce high zone tolerance which is associated with a more complex and more generalized state of immunosuppression. This last state is probably responsible for the marked loss in immunity when this tumour grows large and may allow metastases to develop (Milas et al., 1974) .
Low zone tolerance may account for several aspects of tumour behaviour. One of these is 'sneaking through' (Kolsch et al., 1973; Mengersen et al., 1975; Haubeck & Kolsch, 1982) . One would predict that for 'sneaking through' to be explained on this basis there would have to be a dose window where tumour take is inibited by the development of immunity but this manifestation of immunity can be masked by larger tumour cell numbers. Below this window tolerance would be induced. Furthermore to see 'sneaking through', the transplanted tumour must be sufficiently resistant to natural immune mechanisms and sufficiently clonogenic to grow from cell doses that induce tolerance. These requirements would explain why 'sneaking through' is not seen with all tumours and opens up the possibility that low zone Ts cell induction may be a more general phenomenon.
It is possible that tumours, even ones capable of inducing immunity, might have initially escaped the attentions of the host immune system by inducing tolerance. It would be interesting to study the highly immunogenic UV-induced tumours in this regard. It should be noted that, with the possible exception of certain virus-coded products, there is no compelling reason to consider tumour antigens as being anything other than self or minimally altered self components, perhaps exceptional only in the amount and timing of their expression. One might expect responses to such antigens to be under close suppressor cell control. Under natural conditions anti-tumour responses might therefore require breakage of a tolerant state and could be considered as largely autoimmune in nature.
Finally, we previously noted that immunotherapy of this tumour with C. parvum was only effective when inocula of moderate size were used (Peters et al., 1978) . Not only were small-size inocula not rejected but tumour take was actually enhanced. We can now explain the lack of effect of C. parvum on small size inocula as being due to the presence of a tolerant state.
These studies reemphasize the need for extreme care when drawing conclusions from experiments where single doses of transplanted tumours are used and suggest that tolerant mice might be a useful tool for studying the effects of the immune system and immuno-therapy on tumour behaviour.
